DOI: 10.12890/2024_004675

Unforeseen complications of pembrolizumab in breast reconstruction post-mastectomy

Authors

  • Murad Aldarayseh Internal Medicine Department, RWJ Barnabas Health/Trinitas Regional Medical Center, Elizabeth, USA
  • Sohail Singh Sodhi Internal Medicine Department, RWJ Barnabas Health/Trinitas Regional Medical Center, Elizabeth, USA
  • Gamal Musleh Internal Medicine Department, RWJ Barnabas Health/Trinitas Regional Medical Center, Elizabeth, USA
  • Dyuti Kumar St George’s University School of Medicine, Grenada, West Indies
  • Michelle Cholankeril Internal Medicine Department, RWJ Barnabas Health/Trinitas Regional Medical Center, Elizabeth, USA

GAMAL1187SGU@GMAIL.COM

Keywords

Pembrolizumab, breast reconstruction, breast cancer

Abstract

A 53-year-old post-menopausal Indian female presented with invasive ductal carcinoma, treated with neoadjuvant chemotherapy and pembrolizumab due to a PD-L1 combined positive score of 5. Following a right mastectomy and axillary dissection, she received a breast expander and AlloDerm™ graft. After resuming pembrolizumab and paclitaxel postoperatively, she developed severe breast redness and high-grade fever, necessitating expander removal due to suspected pembrolizumab-induced complications. This case underscores the unique and severe adverse effects of pembrolizumab on breast reconstruction, highlighting the need for careful monitoring and management in patients undergoing similar treatments.

View the entire article

Downloads

References

  1. Poole RM. Pembrolizumab: first global approval. Drugs 2014;74:1973–1981.
  2. Schmid P, Cortes J, Pusztai L, McArthur H, Kümmel S, Bergh J, et al. KEYNOTE-522 Investigators. Pembrolizumab for early triple-negative breast cancer. N Engl J Med 2020;382:810–821.
  3. Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA Oncol 2016;2:1346–1353.
  4. Ni D, AlZahrani F, Smylie M. AIHA and pancytopenia as complications of pembrolizumab therapy for metastatic melanoma: a case report. Case Rep Oncol 2019;12:456–465.
  5. Chae YK, Chiec L, Mohindra N, Gentzler R, Patel J, Giles F. A case of pembrolizumab-induced type-1 diabetes mellitus and discussion of immune checkpoint inhibitor-induced type 1 diabetes. Cancer Immunol Immunother 2017;66:25–32.
  6. Lipson EJ, Naqvi FF, Loss MJ, Schollenberger MD, Pardoll DM, Moore J Jr, et al. Kidney retransplantation after anti-programmed cell death-1 (PD-1)-related allograft rejection. Am J Transplant 2020;20:2264–2268.
  7. Cui X, Yan C, Xu Y, Li D, Guo M, Sun L, Zhu Z. Allograft rejection following immune checkpoint inhibitors in solid organ transplant recipients: a safety analysis from a literature review and a pharmacovigilance system. Cancer Med 2023;12:5181–5194.
  8. Aguirre LE, Guzman ME, Lopes G, Hurley J. Immune checkpoint inhibitors and the risk of allograft rejection: a comprehensive analysis on an emerging issue. Oncologist 2019; 24:394–401.
  9. Berry T, Brooks S, Sydow N, Djohan R, Nutter B, Lyons J, et al. Complication rates of radiation on tissue expander and autologous tissue breast reconstruction. Ann Surg Oncol 2010;17(Suppl. 3):202–210.

Published

2024-07-01

Issue

Vol. 11 No. 7 (2024)

Categories

How to Cite

1.
Aldarayseh M, Sodhi SS, Musleh G, Kumar D, Cholankeril M. Unforeseen complications of pembrolizumab in breast reconstruction post-mastectomy. EJCRIM [Internet]. 2024 Jul. 1 [cited 2026 Nov. 3];11(7). Available from: https://ejcrim.com/index.php/ejcrim/article/view/4675

Most read articles by the same author(s)